undamentalytics Newsletter

Merck & Co. insider trading

Every open-market purchase and sale by Merck & Co.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Merck & Co. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Merck & Co.’s insiders pay?

From February 24, 2010 to August 13, 2026, 43 insiders reported 5 open-market purchases and 151 sales not made under a pre-set plan in Merck & Co. Twelve months after each purchase was reported, the shares were +17.8% against the S&P 500 on average (median +23.3%), over 5 purchases with a full year of prices; 80% beat the index. After sales, the shares moved −7.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 16, 2011 into $27,157 by November 2, 2026, +6.8% a year. It held shares 17% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,202 (+4.4% a year), and held throughout $82,565 (+14.9%).

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $82.6k$27.2k$19.2k
Copying Merck & Co.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Merck & Co.'s insiders from August 16, 2011, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 17% of the time.
Merck & Co.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Deluca Richard R. EVP&Pres, Merck Animal Heallth 0 — — 11 −0.6% (8) August 12, 2026
Frazier Kenneth C Executive Chair 1 +23.3% (1) 100% 8 −4.4% (8) November 8, 2022
Mizell Steven EVP, Chief HR Officer 0 — — 8 −13.6% (8) February 2, 2024
Oosthuizen Johannes Jacobus President, U.S. Market 0 — — 7 −15.0% (6) February 6, 2026
Weeks Wendell P Director 0 — — 7 −7.5% (7) May 7, 2020
Deese Willie A Exe V-P & Pres. MMD 0 — — 6 −1.8% (6) February 11, 2015
Karachun Rita A Sr. VP Fince-Global Controller 0 — — 6 −0.1% (6) May 5, 2023
Williams David Michael EVP,Chief Info&Digital Officer 0 — — 6 −10.4% (3) August 7, 2026
Zachary Jennifer EVP, General Counsel 0 — — 6 −19.3% (4) August 13, 2026
Bowles Richard S III Exe VP&Chief Ethics & ComplOff 0 — — 5 0.0% (5) May 10, 2012
Davis Robert M Chairman, CEO & President 0 — — 5 −22.1% (4) February 6, 2026
Gerberding Julie L. EVP, Chief Patient Officer 0 — — 5 +5.4% (5) November 3, 2021
Guindo Chirfi EVP, Access, Policy & Comms 0 — — 5 — August 13, 2026
Wendell Peter C Director 0 — — 5 −12.3% (5) February 6, 2017
Chattopadhyay Sanat Exe V-P & Pres. MMD 0 — — 4 −8.7% (4) November 1, 2022
Clyburn Frank EVP & Pres ? Human Health 0 — — 4 +6.4% (4) November 2, 2021
Golestani Clark EVP & Chief Info Officer 0 — — 4 −5.7% (4) August 10, 2016
Kuhlik Bruce N Exe V-P & Gen Counsel 0 — — 4 −6.3% (4) May 5, 2015
Ambrose Adele D Sr.V-P & Chief Comuns Officer 0 — — 3 +5.1% (3) October 29, 2015
Barshay Stanley F ExVP&PresConsHlthCare 0 — — 3 −26.5% (3) March 5, 2010
Heller Bridgette P Exe.VP & Pres.Con.Hlth.Care 0 — — 3 +3.1% (3) February 14, 2014
Holston Michael J EVP, General Counsel 0 — — 3 −11.2% (3) February 6, 2017
Li Dean Y Executive VP & President, MRL 0 — — 3 −57.0% (1) February 10, 2026
Litchfield Caroline EVP & CFO 0 — — 3 −4.5% (2) February 6, 2026
Romanelli Joseph President, Human Health Int?l 1 −13.0% (1) 0% 2 −28.9% (2) February 14, 2024
Schechter Adam H EVP & Pres-Global Human Health 0 — — 3 −11.3% (3) May 11, 2015
Brun Leslie A Director 0 — — 2 −28.1% (2) May 7, 2020
Canan John Sr.V-P Finc-Global Controller 0 — — 2 −8.3% (2) February 11, 2014
Cech Thomas R Director 0 — — 2 −5.7% (2) February 6, 2017
Downing Cristal N Chief Comm. & Public Afrs Ofcr 0 — — 2 +27.5% (1) November 12, 2025
Glocer Thomas H Director 0 — — 2 +10.8% (2) February 4, 2019
Kohan Raul E Exe V-P & Pres, Animal Health 0 — — 2 −11.5% (2) May 19, 2011
Lazarus Rochelle B Director 0 — — 2 −19.8% (2) November 2, 2016
Smart Dalton E. III SVP Fin. - Global Controller 0 — — 2 +5.0% (1) February 6, 2026
Baker Douglas M Jr Director 1 +27.5% (1) 100% 0 — February 7, 2025
Kellogg Peter N Exe V-P & CFO 1 +23.3% (1) 100% 0 — August 15, 2011
Kidder C Robert Director 0 — — 1 −18.8% (1) May 12, 2017
Kim Peter S Exe V-P & Pres, MRL 0 — — 1 −21.0% (1) November 6, 2012
Maraldo David R. EVP & Pres. MMD 0 — — 1 — August 7, 2026
Perlmutter Roger M Exe V-P & Pres, MRL 0 — — 1 +2.0% (1) November 8, 2018

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). The 40 most active of 43 insiders are shown. A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Merck & Co.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Merck & Co. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +3.7% against the index. After 15 selling crowds, −1.6%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
August 31, 20265 sellingnot yetnot yetnot yet
February 27, 20269 selling−14.0%+8.8%not yet
February 28, 20253 selling−15.5%−16.3%+18.9%
February 29, 20248 selling−4.6%−17.1%−40.2%
November 30, 20228 selling−1.9%−2.3%−17.9%
November 30, 20216 selling+6.9%+33.4%+61.3%
October 30, 20203 selling−13.1%−25.5%−16.2%
February 28, 20195 selling−1.9%+3.2%−11.6%
November 30, 20184 selling+1.3%+0.7%−1.4%
November 30, 20163 selling+0.8%−3.3%−29.7%
October 30, 20153 selling+1.0%+2.3%+6.6%
April 30, 20154 selling−2.6%−7.2%−5.9%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Latest 12 of 17. Total returns from the month end; past patterns are not a forecast.

← Back to Merck & Co. · Funds · Politicians